We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Licenses NexMed's Technology for Topical Lamisil
Novartis Licenses NexMed's Technology for Topical Lamisil
September 15, 2005
NexMed has licensed its nail fungus treatment to Novartis Pharmaceuticals, maker of nail antifungal Lamisil, which could allow Novartis to create a topical version of Lamisil as effective as the oral drug but with fewer side effects.